an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in Greater China. “We are pleased to see CFT8919, our fourth small molecule degrader to enter the ...

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I ...